Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Antonio Casado Herraez"'
Autor:
William P. McGuire, Richard T. Penson, Martin Gore, Antonio Casado Herraez, Patrick Peterson, Ashwin Shahir, Robert Ilaria
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. Thi
Externí odkaz:
https://doaj.org/article/aec05d6fed2e4b8d95e91fcd8dfd28b0
Autor:
Dide den Hollander, Marco Fiore, Javier Martin-Broto, Bernd Kasper, Antonio Casado Herraez, Dagmara Kulis, Ioanna Nixon, Samantha C. Sodergren, Martin Eichler, Winan J. van Houdt, Ingrid M. E. Desar, Isabelle Ray-Coquard, Claire Piccinin, Hanna Kosela-Paterczyk, Aisha Miah, Leopold Hentschel, Susanne Singer, Roger Wilson, Winette T. A. van der Graaf, Olga Husson
Publikováno v:
Cancers, Vol 13, Iss 1, p 1 (2020)
Sarcomas comprise 1% of adult tumors and are very heterogeneous. Long-lasting and cumulative treatment side-effects detract from the (progression-free) survival benefit of treatment. Therefore, it is important to assess treatment effectiveness in ter
Externí odkaz:
https://doaj.org/article/575d95af2a8f4695834154b23a7fe969
Autor:
Domenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, Alessandro D. Santin, Emeline Colomba, David Scott Miller, Keiichi Fujiwara, Sandro Pignata, Sally E. Baron-Hay, Isabelle Laure Ray-Coquard, Ronnie Shapira-Frommer, Yong Man Kim, Mary McCormack, Rachid Massaad, Allison Martin Nguyen, Qi Zhao, Jodi McKenzie, Vimalanand S. Prabhu, Vicky Makker
Publikováno v:
European Journal of Cancer. 186:172-184
Purpose: Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase
Autor:
Lea Dutta, Vicky Makker, Melissa Zale, Matthew H. Taylor, Ana Oaknin, David M. O'Malley, Antonio Casado Herraez, Robert Orlowski, Min Ren
Publikováno v:
The Oncologist
Background The combination of lenvatinib plus pembrolizumab has shown efficacy in treatment of advanced endometrial carcinoma (that is not microsatellite instability–high or mismatch repair deficient) following prior systemic therapy in any setting
Autor:
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, Tomasz Byrski, Patricia Pautier, Philipp Harter, Nicoletta Colombo, Giovanni Scambia, Maria Nicoletto, Fiona Nussey, Andrew Clamp, Richard Penson, Amit Oza, Andrés Poveda Velasco, Manuel Rodrigues, Jean-Pierre Lotz, Frédéric Selle, Isabelle Ray-Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare Scott, Mayu Yunokawa, Jacques Medioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie-Christine Kaminsky, Béatrice Weber, Alain Lortholary, Christine Parkinson, Jonathan Ledermann, Sarah Williams, Susana Banerjee, Jonathan Cosin, James Hoffman, Marie Plante, Allan Covens, Gabe Sonke, Florence Joly, Holger Hirte, Amnon Amit, Koji Matsumoto, Sergei Tjulandin, Jae Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David O'Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, Maria Pilar Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez De Liaño Lista, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella Ottevanger, Joo-Hyun Nam, Elias Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie McKenzie, Gustavo Rodriguez, Deborah Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan Davidson, Stephen Welch, Limor Helpman, Ami Fishman, Ilan Bruchim, Magdalena Sikorska, Anna Słowińska, Wojciech Rogowski, Mariusz Bidziński, Beata Śpiewankiewicz, Antonio Casado Herraez, César Mendiola Fernández, Martina Gropp-Meier, Toshiaki Saito, Kazuhiro Takehara, Takayuki Enomoto, Hidemichi Watari, Chel Hun Choi, Byoung-Gie Kim, Jae Weon Kim, Roberto Hegg
Publikováno v:
Lancet Oncology, 22, 5, pp. 620-631
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group
Contains fulltext : 241226.pdf (Publisher’s version ) (Closed access) BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with re
Autor:
Vicky Makker, Alessandro D. Santin, Keiichi Fujiwara, Min Ren, Ulus Ali Sanli, Nicoletta Colombo, David Miller, M Orlando, EM Guerra, Yong Man Kim, R Kristeleit, Bradley J. Monk, Emeline Colomba, Sandro Pignata, Robert Orlowski, Domenica Lorusso, K Yonemori, Antonio Casado Herraez, Lea Dutta
Publikováno v:
Endometrial cancer.
Introduction/Background* In Study 309/KEYNOTE-775, lenvatinib+pembrolizumab showed significant and clinically meaningful improvements in OS, PFS, and ORR versus treatment of physician’s choice (TPC) in aEC patients following prior platinum-based th
Autor:
Jose Alejandro Perez-Fidalgo, Ana Cristina Cercos Lleti, Luis Manso, Antonio Casado Herraez, Pedro Ventayol Bosch, Carla Garí, Miriam Padres Martí, Sergio Cedillo Gomez
Publikováno v:
Journal of Clinical Oncology. 40:e17591-e17591
e17591 Background: Olaparib, a poly (ADP-ribose) polymerase inhibitor (PARPi), monotherapy as first-line maintenance treatment has shown to be cost-effective in ovarian cancer (OC) patients with BRCA mutations in Spain. Regardless of BRCA status, pat
Autor:
Richard T. Penson, Rebecca Christian Arend, Angeles Alvarez Secord, Antonio Casado Herraez, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Shifra Fain Shmueli, Bradley J. Monk
Publikováno v:
Journal of Clinical Oncology. 40:TPS5606-TPS5606
TPS5606 Background: Ofranergene obadenovec (Ofra-vec, VB-111) is an anti-cancer gene based immune activator and targeted vascular disruptor. The dual mechanism of action triggers a broad antiangiogenic effect and induces of a tumor directed immune re
Autor:
Javier Martin Broto, Jeronimo Martinez Garcia, David Silva Moura, Andres Redondo, Antonio Gutierrez, Antonio Lopez-Pousa, Javier Martinez-Trufero, Isabel Sevilla, Robert Diaz Beveridge, Maria Pilar Solis-Hernandez, Amancio Carnero, Marco Perez, David Marcilla, Jose A. Lopez-Martin, Antonio Casado Herraez, Rosa Maria Alvarez Alvarez, Josefina Cruz Jurado, Anna Estival-Gonzalez, Patricio Ledesma, Nadia Hindi
Publikováno v:
Journal of Clinical Oncology. 40:11511-11511
11511 Background: CDK4/6 inhibitors showed a favorable progression-free survival (PFS) in DD LPS, a sarcoma bearing 12q 13-15 amplicon that implies CDK4 amplification. The median PFS was 4 and 7 months (m) for palbociclib and abemaciclib, respectivel
Autor:
Pallavi Sachdev, Vicky Makker, Marcia S. Brose, Ana Oaknin, Mark Messing, Antonio Casado Herraez, Emmett V. Schmidt, Daniel E. Stepan, Christopher DiSimone, Margarita Romeo, Raquel Bratos, Carol Aghajanian, Allen Lee Cohn, James W. Mier, Robert Orlowski, Corina E. Dutcus, Jane Wu, Matthew H. Taylor, Robert Shumaker
Publikováno v:
Journal of Clinical Oncology
Scientia
Scientia
PURPOSE Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phas